Skip to content

TriangleGet started

← Full study record

NCT01871805 · OUTCOME

Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13): Phase II

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) · Source last updated 2018-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: units on a scale
Interval / dispersion: Standard Deviation
Time frame: Baseline, Weeks 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 105, 111, 117, last visit (up to 194 weeks)

What was measured

EORTC QLQ-LC13 consisted of 13 questions for dyspnea (3 items) and 10 single items (cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm/shoulder, other pain). Questions used 4-point scale (1 'Not at all' to 4 'Very much'). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning, lower score indicates lower level of functioning. 'Baseline' category for any parameter below represents absolute data at baseline.

Analysis population: Phase II safety population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure. 'Number Analyzed' = number of participants evaluable at the specified timepoint.

Groups in this outcome

Alectinib 600 mg (Fed): Phase II

Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Reported measurements

Dyspnoea: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	76

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	30.85	27.13	Not reported	Not reported	Not reported

Dyspnoea: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	58

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.24	22.57	Not reported	Not reported	Not reported

Dyspnoea: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	48

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.64	20.65	Not reported	Not reported	Not reported

Dyspnoea: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	47

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.35	21.67	Not reported	Not reported	Not reported

Dyspnoea: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.41	21.68	Not reported	Not reported	Not reported

Dyspnoea: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.56	7.86	Not reported	Not reported	Not reported

Dyspnoea: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.09	20.41	Not reported	Not reported	Not reported

Dyspnoea: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	11.11	Not reported	Not reported	Not reported

Dyspnoea: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	37

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.41	21.69	Not reported	Not reported	Not reported

Dyspnoea: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	7.86	Not reported	Not reported	Not reported

Dyspnoea: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.64	20.25	Not reported	Not reported	Not reported

Dyspnoea: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.78	27.78	Not reported	Not reported	Not reported

Dyspnoea: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.74	24.77	Not reported	Not reported	Not reported

Dyspnoea: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-27.78	23.57	Not reported	Not reported	Not reported

Dyspnoea: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.02	19.63	Not reported	Not reported	Not reported

Dyspnoea: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.22	16.48	Not reported	Not reported	Not reported

Dyspnoea: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	29

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.28	19.54	Not reported	Not reported	Not reported

Dyspnoea: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	3.70	16.97	Not reported	Not reported	Not reported

Dyspnoea: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	25

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.22	25.27	Not reported	Not reported	Not reported

Dyspnoea: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-13.89	29.22	Not reported	Not reported	Not reported

Dyspnoea: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.76	26.96	Not reported	Not reported	Not reported

Dyspnoea: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	7.86	Not reported	Not reported	Not reported

Dyspnoea: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	19

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.19	22.48	Not reported	Not reported	Not reported

Dyspnoea: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	7.86	Not reported	Not reported	Not reported

Dyspnoea: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-9.40	16.26	Not reported	Not reported	Not reported

Dyspnoea: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.41	23.13	Not reported	Not reported	Not reported

Dyspnoea: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	17.82	Not reported	Not reported	Not reported

Dyspnoea: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	22.22	0.00	Not reported	Not reported	Not reported

Dyspnoea: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-51.85	23.13	Not reported	Not reported	Not reported

Dyspnoea: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	69

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.44	23.45	Not reported	Not reported	Not reported

Coughing: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	33.76	27.47	Not reported	Not reported	Not reported

Coughing: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	60

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-13.89	31.47	Not reported	Not reported	Not reported

Coughing: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Coughing: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	52

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-12.82	27.34	Not reported	Not reported	Not reported

Coughing: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Coughing: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	49

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-13.61	24.46	Not reported	Not reported	Not reported

Coughing: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Coughing: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	40

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-9.17	31.11	Not reported	Not reported	Not reported

Coughing: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Coughing: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.75	24.44	Not reported	Not reported	Not reported

Coughing: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-22.22	19.25	Not reported	Not reported	Not reported

Coughing: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.77	28.67	Not reported	Not reported	Not reported

Coughing: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-50.00	23.57	Not reported	Not reported	Not reported

Coughing: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-0.93	27.01	Not reported	Not reported	Not reported

Coughing: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	50.00	Not reported	Not reported	Not reported

Coughing: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.04	35.12	Not reported	Not reported	Not reported

Coughing: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-33.33	0.00	Not reported	Not reported	Not reported

Coughing: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	25.40	Not reported	Not reported	Not reported

Coughing: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-20.00	29.81	Not reported	Not reported	Not reported

Coughing: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	29

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.30	29.45	Not reported	Not reported	Not reported

Coughing: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	33.33	Not reported	Not reported	Not reported

Coughing: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.13	27.80	Not reported	Not reported	Not reported

Coughing: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-25.00	31.91	Not reported	Not reported	Not reported

Coughing: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.25	28.35	Not reported	Not reported	Not reported

Coughing: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Coughing: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	20

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.67	35.21	Not reported	Not reported	Not reported

Coughing: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Coughing: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-15.38	29.24	Not reported	Not reported	Not reported

Coughing: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	33.33	Not reported	Not reported	Not reported

Coughing: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	29.55	Not reported	Not reported	Not reported

Coughing: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Coughing: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-44.44	19.25	Not reported	Not reported	Not reported

Coughing: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Coughing: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Coughing: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Coughing: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Coughing: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.48	32.87	Not reported	Not reported	Not reported

Hemoptysis: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.27	6.41	Not reported	Not reported	Not reported

Hemoptysis: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	60

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.11	6.03	Not reported	Not reported	Not reported

Hemoptysis: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Hemoptysis: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	52

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.28	6.47	Not reported	Not reported	Not reported

Hemoptysis: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Hemoptysis: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	49

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.36	6.66	Not reported	Not reported	Not reported

Hemoptysis: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Hemoptysis: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	40

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.67	7.36	Not reported	Not reported	Not reported

Hemoptysis: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	13.25	Not reported	Not reported	Not reported

Hemoptysis: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.75	7.54	Not reported	Not reported	Not reported

Hemoptysis: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	7.97	Not reported	Not reported	Not reported

Hemoptysis: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.01	5.80	Not reported	Not reported	Not reported

Hemoptysis: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.08	10.48	Not reported	Not reported	Not reported

Hemoptysis: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	29

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.15	6.19	Not reported	Not reported	Not reported

Hemoptysis: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.28	6.54	Not reported	Not reported	Not reported

Hemoptysis: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.90	22.28	Not reported	Not reported	Not reported

Hemoptysis: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	20

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.67	7.45	Not reported	Not reported	Not reported

Hemoptysis: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.56	9.25	Not reported	Not reported	Not reported

Hemoptysis: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Hemoptysis: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Hemoptysis: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Hemoptysis: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Hemoptysis: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Hemoptysis: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-0.91	7.80	Not reported	Not reported	Not reported

Sore mouth: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.06	16.09	Not reported	Not reported	Not reported

Sore mouth: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	60

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.11	13.68	Not reported	Not reported	Not reported

Sore mouth: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Sore mouth: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	52

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.64	13.99	Not reported	Not reported	Not reported

Sore mouth: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Sore mouth: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	49

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.04	17.22	Not reported	Not reported	Not reported

Sore mouth: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Sore mouth: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-0.85	17.91	Not reported	Not reported	Not reported

Sore mouth: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Sore mouth: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.56	11.81	Not reported	Not reported	Not reported

Sore mouth: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	22.22	38.49	Not reported	Not reported	Not reported

Sore mouth: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.75	15.40	Not reported	Not reported	Not reported

Sore mouth: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Sore mouth: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-0.93	9.71	Not reported	Not reported	Not reported

Sore mouth: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Sore mouth: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.07	26.03	Not reported	Not reported	Not reported

Sore mouth: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Sore mouth: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.08	13.56	Not reported	Not reported	Not reported

Sore mouth: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	23.57	Not reported	Not reported	Not reported

Sore mouth: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	29

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.15	14.04	Not reported	Not reported	Not reported

Sore mouth: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Sore mouth: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.56	13.07	Not reported	Not reported	Not reported

Sore mouth: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Sore mouth: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	22

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.55	18.67	Not reported	Not reported	Not reported

Sore mouth: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Sore mouth: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	20

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.67	7.45	Not reported	Not reported	Not reported

Sore mouth: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Sore mouth: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Sore mouth: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Sore mouth: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.17	11.79	Not reported	Not reported	Not reported

Sore mouth: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Sore mouth: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Sore mouth: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Sore mouth: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Sore mouth: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Sore mouth: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Sore mouth: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-0.46	15.21	Not reported	Not reported	Not reported

Dysphagia: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.64	11.61	Not reported	Not reported	Not reported

Dysphagia: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	60

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.67	11.36	Not reported	Not reported	Not reported

Dysphagia: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dysphagia: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	52

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-0.64	10.42	Not reported	Not reported	Not reported

Dysphagia: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dysphagia: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	49

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.36	11.70	Not reported	Not reported	Not reported

Dysphagia: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dysphagia: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	40

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.83	11.91	Not reported	Not reported	Not reported

Dysphagia: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Dysphagia: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	3.42	14.90	Not reported	Not reported	Not reported

Dysphagia: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	33.33	Not reported	Not reported	Not reported

Dysphagia: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-0.88	5.41	Not reported	Not reported	Not reported

Dysphagia: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Dysphagia: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-0.93	12.56	Not reported	Not reported	Not reported

Dysphagia: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	27.22	Not reported	Not reported	Not reported

Dysphagia: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.02	16.54	Not reported	Not reported	Not reported

Dysphagia: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Dysphagia: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.08	13.56	Not reported	Not reported	Not reported

Dysphagia: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	6.67	27.89	Not reported	Not reported	Not reported

Dysphagia: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	28

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.57	13.88	Not reported	Not reported	Not reported

Dysphagia: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Dysphagia: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.28	14.85	Not reported	Not reported	Not reported

Dysphagia: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Dysphagia: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.45	15.82	Not reported	Not reported	Not reported

Dysphagia: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Dysphagia: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	20

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	10.81	Not reported	Not reported	Not reported

Dysphagia: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Dysphagia: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.56	9.25	Not reported	Not reported	Not reported

Dysphagia: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Dysphagia: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Dysphagia: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Dysphagia: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Dysphagia: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dysphagia: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dysphagia: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dysphagia: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dysphagia: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.74	17.35	Not reported	Not reported	Not reported

Peripheral neuropathy: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	13.08	22.28	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	60

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	6.11	17.88	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	52

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.28	20.83	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	49

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.72	22.40	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	40

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.17	20.24	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.27	24.40	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	18.98	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.85	21.00	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.33	16.67	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.02	23.48	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	6.45	26.41	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	6.67	27.89	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	29

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.30	23.45	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.28	24.00	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.90	28.27	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	20

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.33	21.36	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	12.82	37.36	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	17.82	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	55.56	38.49	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Peripheral neuropathy: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Peripheral neuropathy: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.37	22.52	Not reported	Not reported	Not reported

Alopecia: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	77

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.69	25.80	Not reported	Not reported	Not reported

Alopecia: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	59

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.13	22.29	Not reported	Not reported	Not reported

Alopecia: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Alopecia: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	51

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.31	31.24	Not reported	Not reported	Not reported

Alopecia: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Alopecia: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	47

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.96	25.04	Not reported	Not reported	Not reported

Alopecia: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Alopecia: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.56	27.98	Not reported	Not reported	Not reported

Alopecia: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Alopecia: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.51	27.72	Not reported	Not reported	Not reported

Alopecia: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Alopecia: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	37

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.90	32.85	Not reported	Not reported	Not reported

Alopecia: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Alopecia: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.78	20.12	Not reported	Not reported	Not reported

Alopecia: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Alopecia: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.21	22.58	Not reported	Not reported	Not reported

Alopecia: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Alopecia: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.45	15.91	Not reported	Not reported	Not reported

Alopecia: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.67	14.91	Not reported	Not reported	Not reported

Alopecia: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	29

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.60	19.36	Not reported	Not reported	Not reported

Alopecia: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	19.25	Not reported	Not reported	Not reported

Alopecia: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	25

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.67	27.08	Not reported	Not reported	Not reported

Alopecia: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	16.67	Not reported	Not reported	Not reported

Alopecia: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	22

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.03	33.98	Not reported	Not reported	Not reported

Alopecia: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Alopecia: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	20

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	26.21	Not reported	Not reported	Not reported

Alopecia: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Alopecia: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.56	25.32	Not reported	Not reported	Not reported

Alopecia: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	19.25	Not reported	Not reported	Not reported

Alopecia: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.17	21.36	Not reported	Not reported	Not reported

Alopecia: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Alopecia: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Alopecia: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Alopecia: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Alopecia: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Alopecia: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Alopecia: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	71

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.16	27.97	Not reported	Not reported	Not reported

Pain in chest: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	21.52	28.26	Not reported	Not reported	Not reported

Pain in chest: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	60

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	29.75	Not reported	Not reported	Not reported

Pain in chest: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in chest: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	52

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.54	23.69	Not reported	Not reported	Not reported

Pain in chest: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in chest: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	49

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.84	27.87	Not reported	Not reported	Not reported

Pain in chest: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in chest: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	40

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	23.57	Not reported	Not reported	Not reported

Pain in chest: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Pain in chest: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.42	22.68	Not reported	Not reported	Not reported

Pain in chest: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	19.25	Not reported	Not reported	Not reported

Pain in chest: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.14	26.68	Not reported	Not reported	Not reported

Pain in chest: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Pain in chest: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.48	19.22	Not reported	Not reported	Not reported

Pain in chest: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	41.94	Not reported	Not reported	Not reported

Pain in chest: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.06	19.46	Not reported	Not reported	Not reported

Pain in chest: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-33.33	0.00	Not reported	Not reported	Not reported

Pain in chest: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.30	20.62	Not reported	Not reported	Not reported

Pain in chest: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-13.33	38.01	Not reported	Not reported	Not reported

Pain in chest: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	29

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.45	16.29	Not reported	Not reported	Not reported

Pain in chest: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Pain in chest: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.56	18.67	Not reported	Not reported	Not reported

Pain in chest: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-25.00	31.91	Not reported	Not reported	Not reported

Pain in chest: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.90	28.27	Not reported	Not reported	Not reported

Pain in chest: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Pain in chest: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	20

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	18.73	Not reported	Not reported	Not reported

Pain in chest: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Pain in chest: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.13	22.96	Not reported	Not reported	Not reported

Pain in chest: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	19.25	Not reported	Not reported	Not reported

Pain in chest: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-12.50	24.80	Not reported	Not reported	Not reported

Pain in chest: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Pain in chest: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-22.22	19.25	Not reported	Not reported	Not reported

Pain in chest: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in chest: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in chest: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in chest: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in chest: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	72

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.80	26.83	Not reported	Not reported	Not reported

Pain in arm or shoulder: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.88	28.18	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	60

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.22	25.37	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	52

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.77	30.05	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	48

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.86	24.78	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	40

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-10.83	27.62	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.42	23.93	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	38.49	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.26	33.36	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	25.82	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.06	21.17	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.08	25.07	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	23.57	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	29

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.30	26.62	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.85	27.21	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	33.33	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.35	28.96	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	19

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.77	24.45	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.69	38.86	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.17	21.36	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	33.33	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in arm or shoulder: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in arm or shoulder: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	29.92	Not reported	Not reported	Not reported

Pain in other parts: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	75

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	44.00	36.42	Not reported	Not reported	Not reported

Pain in other parts: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	57

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.96	42.78	Not reported	Not reported	Not reported

Pain in other parts: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in other parts: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	46

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.59	41.70	Not reported	Not reported	Not reported

Pain in other parts: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in other parts: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	45

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-19.26	41.74	Not reported	Not reported	Not reported

Pain in other parts: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in other parts: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-19.30	36.87	Not reported	Not reported	Not reported

Pain in other parts: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Pain in other parts: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-18.52	37.75	Not reported	Not reported	Not reported

Pain in other parts: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	33.33	Not reported	Not reported	Not reported

Pain in other parts: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-18.52	36.90	Not reported	Not reported	Not reported

Pain in other parts: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	94.28	Not reported	Not reported	Not reported

Pain in other parts: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.16	37.38	Not reported	Not reported	Not reported

Pain in other parts: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	56.93	Not reported	Not reported	Not reported

Pain in other parts: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-12.22	34.45	Not reported	Not reported	Not reported

Pain in other parts: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	47.14	Not reported	Not reported	Not reported

Pain in other parts: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	29

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-14.94	38.41	Not reported	Not reported	Not reported

Pain in other parts: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-13.33	38.01	Not reported	Not reported	Not reported

Pain in other parts: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-15.38	34.29	Not reported	Not reported	Not reported

Pain in other parts: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-44.44	38.49	Not reported	Not reported	Not reported

Pain in other parts: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	22

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-10.61	39.02	Not reported	Not reported	Not reported

Pain in other parts: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	41.94	Not reported	Not reported	Not reported

Pain in other parts: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	20

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-15.00	33.29	Not reported	Not reported	Not reported

Pain in other parts: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Pain in other parts: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	19

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.26	27.81	Not reported	Not reported	Not reported

Pain in other parts: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Pain in other parts: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	11

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-12.12	22.47	Not reported	Not reported	Not reported

Pain in other parts: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-22.22	38.49	Not reported	Not reported	Not reported

Pain in other parts: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	6

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	36.51	Not reported	Not reported	Not reported

Pain in other parts: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	33.33	47.14	Not reported	Not reported	Not reported

Pain in other parts: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-33.33	Not reported	Not reported	Not reported	Not reported

Pain in other parts: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in other parts: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in other parts: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in other parts: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain in other parts: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	69

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-12.56	37.96	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
27.13
value
30.85
denoms
counts
group Id
OG000
value
76
units
Participants
title
Dyspnoea: Baseline
categories
measurements
group Id
OG000
spread
22.57
value
-8.24
denoms
counts
group Id
OG000
value
58
units
Participants
title
Dyspnoea: Week 6
categories
measurements
group Id
OG000
value
0.00
denoms
counts
group Id
OG000
value
1
units
Participants
title
Dyspnoea: Week 9
categories
measurements
group Id
OG000
spread
20.65
value
-7.64
denoms
counts
group Id
OG000
value
48
units
Participants
title
Dyspnoea: Week 12
categories
measurements
group Id
OG000
value
0.00
denoms
counts
group Id
OG000
value
1
units
Participants
title
Dyspnoea: Week 15
categories
measurements
group Id
OG000
spread
21.67
value
-11.35
denoms
counts
group Id
OG000
value
47
units
Participants
title
Dyspnoea: Week 18
categories
measurements
group Id
OG000
value
0.00
denoms
counts
group Id
OG000
value
1
units
Participants
title
Dyspnoea: Week 21
categories
measurements
group Id
OG000
spread
21.68
value
-7.41
denoms
counts
group Id
OG000
value
39
units
Participants
title
Dyspnoea: Week 24
categories
measurements
group Id
OG000
spread
7.86
value
5.56
denoms
counts
group Id
OG000
value
2
units
Participants
title
Dyspnoea: Week 27
categories
measurements
group Id
OG000
spread
20.41
value
-4.09
denoms
counts
group Id
OG000
value
38
units
Participants
title
Dyspnoea: Week 30
categories
measurements
group Id
OG000
spread
11.11
value
-11.11
denoms
counts
group Id
OG000
value
3
units
Participants
title
Dyspnoea: Week 33
categories
measurements
group Id
OG000
spread
21.69
value
-5.41
denoms
counts
group Id
OG000
value
37
units
Participants
title
Dyspnoea: Week 36

denoms

counts
group Id
OG000
value
79
units
Participants

description

EORTC QLQ-LC13 consisted of 13 questions for dyspnea (3 items) and 10 single items (cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm/shoulder, other pain). Questions used 4-point scale (1 'Not at all' to 4 'Very much'). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning, lower score indicates lower level of functioning. 'Baseline' category for any parameter below represents absolute data at baseline.

dispersion Type

Standard Deviation

groups

description
Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.
id
OG000
title
Alectinib 600 mg (Fed): Phase II

param Type

MEAN

population Description

Phase II safety population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure. 'Number Analyzed' = number of participants evaluable at the specified timepoint.

reporting Status

POSTED

time Frame

Baseline, Weeks 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 105, 111, 117, last visit (up to 194 weeks)

title

Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13): Phase II

type

SECONDARY

unit Of Measure

units on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice